Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 20/20 | 0.55 |
| ▸ | ACE | P12821 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17980192 | 1.00 | MME (0.55) | MMEACE | |
| SCHEMBL18724753 | 1.00 | MME (0.55) | MMEACE | |
| SCHEMBL18040125 | 1.00 | MME (0.55) | MMEACE | |
| SCHEMBL16939260 | 0.90 | MME (0.63) | MMEACE | |
| SCHEMBL16979113 | 0.90 | MME (0.63) | MMEACE | |
| SCHEMBL18597832 | 0.90 | MMEL1 (0.46) | MMEACE | |
| SCHEMBL14919312 | 0.90 | MMEL1 (0.46) | MMEACE | |
| SCHEMBL14891060 | 0.90 | MMEL1 (0.46) | MMEACE | |
| SCHEMBL18010010 | 0.89 | MME (0.55) | MMEACE | |
| SCHEMBL12317524 | 0.89 | MME (0.55) | MMEACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9533962-B2 | (2R,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-01-03 | — | — | US | claimed |
| US-20160244416-A1 | (2R,4R)-5-(5'-CHLORO-2'-FLUOROBIPHENYL-4-YL)-2-HYDROXY-4-[(5-METHYLOXAZOLE-2-CARBONYL)AMINO]PENTANOIC ACID | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-08-25 | — | — | US | claimed |
| US-11642332-B2 | (2R,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-05-09 | — | — | US | disclosed |
| US-11642332-B2 | (2R,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-05-09 | — | — | US | disclosed |
| US-11642332-B2 | (2R,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-05-09 | — | — | US | disclosed |
| EP-3256446-B1 | (2S,4R)-5-(5'-CHLORO-2'-FLUOROBIPHENYL-4-YL)-4-(ETHOXYOXALYLAMINO)-2-HYDROXYMETHYL-2-METHYLPENTANOIC ACID AS NEPRILYSIN INHIBITOR | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2022-05-18 | — | — | EP | disclosed |
| EP-3256446-B1 | (2S,4R)-5-(5'-CHLORO-2'-FLUOROBIPHENYL-4-YL)-4-(ETHOXYOXALYLAMINO)-2-HYDROXYMETHYL-2-METHYLPENTANOIC ACID AS NEPRILYSIN INHIBITOR | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2022-05-18 | — | — | EP | disclosed |
| US-20210401808-A1 | (2R,4R)-5-(5'-CHLORO-2'-FLUOROBIPHENYL-4-YL)-2-HYDROXY-4-[(5-METHYLOXAZOLE-2-CARBONYL)AMINO]PENTANOIC ACID | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-12-30 | — | — | US | disclosed |
| US-20210401808-A1 | (2R,4R)-5-(5'-CHLORO-2'-FLUOROBIPHENYL-4-YL)-2-HYDROXY-4-[(5-METHYLOXAZOLE-2-CARBONYL)AMINO]PENTANOIC ACID | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-12-30 | — | — | US | disclosed |
| US-11174219-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-11-16 | — | — | US | disclosed |
| US-11174219-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-11-16 | — | — | US | disclosed |
| US-20160228395-A1 | (2S,4R)-5-(5'-CHLORO-2'-FLUOROBIPHENYL-4-YL)-4-(ETHOXYOXALYLAMINO)-2-HYDROXYMETHYL-2-METHYLPENTANOIC ACID | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-08-11 | — | — | US | disclosed |
| US-20160002148-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-01-07 | — | — | US | disclosed |
| US-20160002148-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-01-07 | — | — | US | disclosed |
| US-20160002148-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-01-07 | — | — | US | disclosed |
| US-9108934-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-08-18 | — | — | US | disclosed |
| US-9108934-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-08-18 | — | — | US | disclosed |
| WO-2015116786-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-08-06 | — | — | WO | disclosed |
| US-20150210690-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-07-30 | — | — | US | disclosed |
| US-20150210690-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160244416-A1 | (2R,4R)-5-(5'-CHLORO-2'-FLUOROBIPHENYL-4-YL)-2-HYDROXY-4-[(5-METHYLOXAZOLE-2-CARBONYL)AMINO]PENTANOIC ACID | MME, DNPEP, TMPRSS15 | MME 1/4885ACE 5/4885 |
| US-20160002148-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | MME 1/4885ACE 3/4885 |
| US-11174219-B2 | Neprilysin inhibitors | MME, REN, ACE | MME 1/4885ACE 3/4885 |
| US-20210401808-A1 | (2R,4R)-5-(5'-CHLORO-2'-FLUOROBIPHENYL-4-YL)-2-HYDROXY-4-[(5-METHYLOXAZOLE-2-CARBONYL)AMINO]PENTANOIC ACID | MME, DNPEP, TMPRSS15 | MME 1/4885ACE 5/4885 |
| US-20160228395-A1 | (2S,4R)-5-(5'-CHLORO-2'-FLUOROBIPHENYL-4-YL)-4-(ETHOXYOXALYLAMINO)-2-HYDROXYMETHYL-2-METHYLPENTANOIC ACID | MME, DNPEP, CMA1 | MME 1/4885ACE 4/4885 |
| US-20150210690-A1 | NEPRILYSIN INHIBITORS | MME, REN, AGTR1 | MME 1/4885ACE 4/4885 |
| US-11642332-B2 | (2R,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid | MME, DNPEP, TMPRSS15 | MME 1/4885ACE 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.